Contact
New Bolton Center Kennett Square, PA
Emergencies & Appointments:
610-444-5800
Directions
Ryan Hospital Philadelphia, PA
Emergencies:
215-746-8911
Appointments:
215-746-8387
Directions

Use of a Novel Immunotherapy for Dogs with Bone Cancer of the Leg

Oct 25, 2017

Osteosarcoma (OSA) is an aggressive cancer that frequently arises in the long bones of large-breed dogs. Approximately 90-95% of dogs with osteosarcoma have undetectable metastatic disease at presentation. Despite limb amputation and follow-up chemotherapy, most dogs are euthanized due to progressive metastatic disease within a year of diagnosis.

Dogs enrolled in this clinical trial will receive a HER2-targeting bacterial vaccine after amputation and chemotherapy. This immunotherapy has shown promising results in preventing metastatic disease when evaluated in a small number of dogs with osteosarcoma after surgery and chemotherapy.

Inclusion Criteria:

  • Dogs with newly diagnosed OSA who have received no prior treatment for cancer
  • Dogs with OSA of the leg which is amenable to limb amputation
  • Dogs with no evidence of metastasis at the time of enrollment
  • Dogs weighing at least 25kg (55lbs) after amputation
  • Owners are willing to pursue amputation and chemotherapy at Penn Vet

Benefits:

Dogs will receive three doses of Listeria vaccine at no cost. Each dose is given three weeks apart, starting after standard chemotherapy (carboplatin) is completed. Dogs may have the option to receive booster vaccine every 6-8 months thereafter.

Follow-up chest x-rays will also be covered by the study.

Please note: The study does not cover the cost of standard-of-care amputation and chemotherapy. These are required and must be performed at Penn Vet.

Please contact the VCIC at 215-573-0302 or by email at vcic@vet.upenn.edu if you would like more information about this study.

Reference: Mason NJ, Gnanandarajah J, Engiles J, Gray F, Laughlin D, Gaurnier-Hausser A, Wallecha A, Huebner M, Paterson Y. Immunotherapy with a HER2 targeted Listeria induces HER2-specific immunity and demonstrates potential therapeutic effects in a phase I trial in canine osteosarcoma. Clin Cancer Res. 2016 Sep 1;22(17):4380-90

Contact Information:

If you would like more information about this study, please contact the VCIC at: